ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

FDMT vs SANA // EV/EBITDA & P/E VALUATION

4D Molecular Therapeutics Inc. (NASDAQ) VS. Sana Biotechnology Inc. (NASDAQ) • 15-METRIC TALLY: FDMT 3 — SANA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FDMT VS. SANA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC FDMT SANA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -28.30% -35.00% +6.70 FDMT /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -15.53% -17.78% +2.25 FDMT /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.17 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 3/9 +2.00 FDMT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.1 46.1 -2.00 SANA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $706.0M $814.3M -$108.2M SANA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR FDMT REV SANA REV FDMT GROSS % SANA GROSS % FDMT FCF SANA FCF
FY 2025 $85.2M $0 — — -$109.6M -$144.8M
FY 2024 $37.0K $0 — — -$138.4M -$256.6M
FY 2023 $20.7M $0 — — -$75.8M -$253.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FDMT // BETA —
SANA // BETA —